{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:19:24Z","timestamp":1740143964133,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Stiftung Institut f\u00fcr Herzinfarktforschung"},{"DOI":"10.13039\/501100005970","name":"Deutsche Stiftung f\u00fcr Herzforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005970","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018936","name":"Universit\u00e4tsklinikum Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018936","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Community-based interventions may promote awareness and adherence to atrial fibrillation (AF)-related therapies, potentially reducing adverse events. The ARENA project investigated the health status, therapies and events in AF patients in the Rhein\u2013Neckar Region, Germany. The subproject \u201cARENA intervention\u201d studied the effect of community-based interventions on AF-associated outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>From 2016 onward, patients with diagnosed AF were recruited for the observational ARENA registry. In 2018, an intervention period was initiated involving population-based information campaigns on AF diagnosis and therapies. The \u201ccontrol group\u201d was recruited prior to initiation, and the \u201cintervention group\u201d afterward. Patients underwent standardized follow-up\u2009&gt;\u20091\u00a0year after recruitment. Clinical outcomes, therapy and quality of life were compared between the two groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 2769 patients were included. This real-world cohort showed high adherence to oral anticoagulation therapy (OAC) and an increased use of NOACs over vitamin K antagonists over time. In the intervention group (<jats:italic>n<\/jats:italic>\u2009=\u20091362), more patients continued OAC at follow-up (87.1% vs. 81.5%, <jats:italic>P<\/jats:italic>\u2009=\u20090.002). However, this difference was not significant in the patient subgroup with class I\/IIa indications for OAC (90.1% vs. 87.5%, <jats:italic>P<\/jats:italic>\u2009=\u20090.11). AF-related re-hospitalization was lower in the intervention group (6.8% vs. 12.3%, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). There was no significant difference in quality of life. AF-related anxiety was reduced at follow-up. Of note, nearly a quarter of all patients stated that ARENA had influenced their health perception.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Tailored community-based campaigns may raise awareness for AF-related health issues, supporting therapy adherence. Future public strategies to improve quality of life in AF patients should be investigated, as the ARENA project hints at a potential benefit of population-based campaigns.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>ClinicalTrials.gov (Identifier: NCT02978248).<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00392-024-02510-6","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T15:02:23Z","timestamp":1723129343000},"page":"138-149","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Community-based analysis of stroke prevention and effect of public interventions in atrial fibrillation: results from the ARENA project"],"prefix":"10.1007","volume":"114","clinical-trial-number":[{"clinical-trial-number":"nct02978248","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9373-8132","authenticated-orcid":false,"given":"Maura M.","family":"Zylla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belgin","family":"\u00d6zdemir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Hochadel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Zeymer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Akin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armin","family":"Grau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelika","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Waldecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"S\u00fcselbeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Schwacke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Haass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Zahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Borggrefe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen","family":"Senges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Frey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dierk","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"key":"2510_CR1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.005128","author":"SR Reading","year":"2017","unstructured":"Reading SR, Go AS, Fang MC, Singer DE, Liu IA, Black MH, Udaltsova N, Reynolds K, Anticoagulation, Risk Factors in Atrial Fibrillation-Cardiovascular Research Network I (2017) Health literacy and awareness of atrial fibrillation. J Am Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.116.005128","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"2510_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/rth2.12051","volume":"2","author":"AM Wendelboe","year":"2018","unstructured":"Wendelboe AM, Raskob GE, Angchaisuksiri P, Blanco AN, Buller H, Ddungu H, Dvorak JD, Hunt BJ, Hylek EM, Kakkar A, Konstantinides SV, McCumber M, McLintock C, Urano T, Weitz JI (2018) Global public awareness about atrial fibrillation. Res Pract Thromb Haemost 2(1):49\u201357. https:\/\/doi.org\/10.1002\/rth2.12051","journal-title":"Res Pract Thromb Haemost"},{"key":"2510_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2021.106797","volume":"153","author":"HY Hassen","year":"2021","unstructured":"Hassen HY, Ndejjo R, Musinguzi G, Van Geertruyden JP, Abrams S, Bastiaens H (2021) Effectiveness of community-based cardiovascular disease prevention interventions to improve physical activity: a systematic review and meta-regression. Prev Med 153:106797. https:\/\/doi.org\/10.1016\/j.ypmed.2021.106797","journal-title":"Prev Med"},{"issue":"14","key":"2510_CR4","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1056\/NEJMoa1717250","volume":"378","author":"RG Victor","year":"2018","unstructured":"Victor RG, Lynch K, Li N, Blyler C, Muhammad E, Handler J, Brettler J, Rashid M, Hsu B, Foxx-Drew D, Moy N, Reid AE, Elashoff RM (2018) A cluster-randomized trial of blood-pressure reduction in black barbershops. N Engl J Med 378(14):1291\u20131301. https:\/\/doi.org\/10.1056\/NEJMoa1717250","journal-title":"N Engl J Med"},{"issue":"1","key":"2510_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jama.284.1.60","volume":"284","author":"RV Luepker","year":"2000","unstructured":"Luepker RV, Raczynski JM, Osganian S, Goldberg RJ, Finnegan JR Jr, Hedges JR, Goff DC Jr, Eisenberg MS, Zapka JG, Feldman HA, Labarthe DR, McGovern PG, Cornell CE, Proschan MA, Simons-Morton DG (2000) Effect of a community intervention on patient delay and emergency medical service use in acute coronary heart disease: the rapid early action for coronary treatment (REACT) trial. JAMA 284(1):60\u201367. https:\/\/doi.org\/10.1001\/jama.284.1.60","journal-title":"JAMA"},{"issue":"7","key":"2510_CR6","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00059-018-4772-5","volume":"45","author":"S Baumann","year":"2020","unstructured":"Baumann S, Grau A, Senges J, Schneider S, Alonso A, Katus HA, Thomas D, Waldecker B, Haass M, Zahn R, Zeymer U, Akin I, Kruska M, Fischer C, Borggrefe M (2020) ARENA-project atrial fibrillation in the Rhein\u2013Neckar region. Herz 45(7):689\u2013695. https:\/\/doi.org\/10.1007\/s00059-018-4772-5","journal-title":"Herz"},{"issue":"5","key":"2510_CR7","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL, Group ESCSD (2021) ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European society of cardiology (ESC) developed with the special contribution of the European heart rhythm association (EHRA) of the ESC. Eur Heart J 42(5):373\u2013498. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa612","journal-title":"Eur Heart J"},{"issue":"6","key":"2510_CR8","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s40273-018-0615-8","volume":"36","author":"K Ludwig","year":"2018","unstructured":"Ludwig K, Graf von der Schulenburg JM, Greiner W (2018) German value set for the EQ-5D-5L. Pharmacoeconomics 36(6):663\u2013674. https:\/\/doi.org\/10.1007\/s40273-018-0615-8","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"2510_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0274237","volume":"17","author":"L Beier","year":"2022","unstructured":"Beier L, Lu S, Fran\u00e7a LR, Marler S, Lip GYH, Huisman MV, Teutsch C, Halperin JL, Zint K, Diener HC, Baker L, Ma CS, Paquette M, Bartels DB, Dubner SJ, Lyrer P, Senges J, Rothman KJ (2022) Evolution of antithrombotic therapy for patients with atrial fibrillation: the prospective global GLORIA-AF registry program. PLoS ONE 17(10):e0274237. https:\/\/doi.org\/10.1371\/journal.pone.0274237","journal-title":"PLoS ONE"},{"issue":"4","key":"2510_CR10","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022638","volume":"11","author":"NE Vinding","year":"2022","unstructured":"Vinding NE, Kristensen SL, Rorth R, Butt JH, Ostergaard L, Olesen JB, Torp-Pedersen C, Gislason GH, Kober L, Kruuse C, Johnsen SP, Fosbol EL (2022) Ischemic stroke severity and mortality in patients with and without atrial fibrillation. J Am Heart Assoc 11(4):e022638. https:\/\/doi.org\/10.1161\/JAHA.121.022638","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"2510_CR11","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1002\/joa3.12588","volume":"37","author":"M Kozie\u0142","year":"2021","unstructured":"Kozie\u0142 M, Teutsch C, Bayer V, Lu S, Gurusamy VK, Halperin JL, Rothman KJ, Diener HC, Ma CS, Huisman MV, Lip GYH (2021) Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world. J Arrhythm 37(4):990\u20131006. https:\/\/doi.org\/10.1002\/joa3.12588","journal-title":"J Arrhythm"},{"issue":"11","key":"2510_CR12","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981\u2013992. https:\/\/doi.org\/10.1056\/NEJMoa1107039","journal-title":"N Engl J Med"},{"issue":"3","key":"2510_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000515","volume":"3","author":"J Douxfils","year":"2014","unstructured":"Douxfils J, Buckinx F, Mullier F, Minet V, Rabenda V, Reginster JY, Hainaut P, Bruyere O, Dogne JM (2014) Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 3(3):e000515. https:\/\/doi.org\/10.1161\/JAHA.113.000515","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"2510_CR14","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1093\/europace\/euv448","volume":"18","author":"A Hern\u00e1ndez Madrid","year":"2016","unstructured":"Hern\u00e1ndez Madrid A, Potpara TS, Dagres N, Chen J, Larsen TB, Estner H, Todd D, Bongiorni MG, Sciaraffia E, Proclemer A, Cheggour S, Amara W, Blomstrom-Lundqvist C (2016) Differences in attitude, education, and knowledge about oral anticoagulation therapy among patients with atrial fibrillation in Europe: result of a self-assessment patient survey conducted by the European heart rhythm association. Europace 18(3):463\u2013467. https:\/\/doi.org\/10.1093\/europace\/euv448","journal-title":"Europace"},{"issue":"11","key":"2510_CR15","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1345\/aph.1E152","volume":"38","author":"SL Jackson","year":"2004","unstructured":"Jackson SL, Peterson GM, Vial JH (2004) A community-based educational intervention to improve antithrombotic drug use in atrial fibrillation. Ann Pharmacother 38(11):1794\u20131799. https:\/\/doi.org\/10.1345\/aph.1E152","journal-title":"Ann Pharmacother"},{"issue":"2","key":"2510_CR16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.119.005871","volume":"13","author":"A Kapoor","year":"2020","unstructured":"Kapoor A, Amroze A, Vakil F, Crawford S, Der J, Mathew J, Alper E, Yogaratnam D, Javed S, Elhag R, Lin A, Narayanan S, Bartlett D, Nagy A, Shagoury BK, Fischer MA, Mazor KM, Saczynski JS, Ashburner JM, Lopes R, McManus DD (2020) SUPPORT-AF II: supporting use of anticoagulants through provider profiling of oral anticoagulant therapy for atrial fibrillation. Circ Cardiovasc Qual Outcomes 13(2):e005871. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.119.005871","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"9","key":"2510_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074037","volume":"8","author":"DE Clarkesmith","year":"2013","unstructured":"Clarkesmith DE, Pattison HM, Lip GY, Lane DA (2013) Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial. PLoS ONE 8(9):e74037. https:\/\/doi.org\/10.1371\/journal.pone.0074037","journal-title":"PLoS ONE"},{"issue":"10104","key":"2510_CR18","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/S0140-6736(17)32165-7","volume":"390","author":"D Vinereanu","year":"2017","unstructured":"Vinereanu D, Lopes RD, Bahit MC, Xavier D, Jiang J, Al-Khalidi HR, He W, Xian Y, Ciobanu AO, Kamath DY, Fox KA, Rao MP, Pokorney SD, Berwanger O, Tajer C, de Barros ESPGM, Roettig ML, Huo Y, Granger CB, investigators I-A (2017) A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial. Lancet 390(10104):1737\u20131746. https:\/\/doi.org\/10.1016\/S0140-6736(17)32165-7","journal-title":"Lancet"},{"issue":"1","key":"2510_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12875-017-0588-2","volume":"18","author":"V Maikranz","year":"2017","unstructured":"Maikranz V, Siebenhofer A, Ulrich LR, Mergenthal K, Schulz-Rothe S, Kemperdick B, Rauck S, Pregartner G, Berghold A, Gerlach FM, Petersen JJ (2017) Does a complex intervention increase patient knowledge about oral anticoagulation?-a cluster-randomised controlled trial. BMC Fam Pract 18(1):15. https:\/\/doi.org\/10.1186\/s12875-017-0588-2","journal-title":"BMC Fam Pract"},{"issue":"2","key":"2510_CR20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3390\/pharmacy8020054","volume":"8","author":"C Metaxas","year":"2020","unstructured":"Metaxas C, Albert V, Habegger S, Messerli M, Hersberger KE, Arnet I (2020) Patient knowledge about oral anticoagulation therapy assessed during an intermediate medication review in Swiss community pharmacies. Pharmacy 8(2):54","journal-title":"Pharmacy"},{"issue":"5","key":"2510_CR21","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jstrokecerebrovasdis.2004.08.001","volume":"13","author":"FE Munschauer 3rd","year":"2004","unstructured":"Munschauer FE 3rd, Sohocki D, Smith Carrow S, Priore RL (2004) A community education program on atrial fibrillation: implications of pulse self-examination on awareness and behavior. J Stroke Cerebrovasc Dis 13(5):208\u2013213. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2004.08.001","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2510_CR22","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3238\/arztebl.m2023.0009","volume":"120","author":"U Zeymer","year":"2023","unstructured":"Zeymer U, Schneider S, Hochadel M, Kleemann T, Borggrefe M, Akin I, Katus H, Thomas D, Werdan K, Senges J (2023) The management of atrial fibrillation with oral anticoagulant drugs\u2014an analysis of guideline adherence in the setting of the ARENA project. Dtsch Arztebl Int 120:324\u2013325. https:\/\/doi.org\/10.3238\/arztebl.m2023.0009","journal-title":"Dtsch Arztebl Int"},{"issue":"14","key":"2510_CR23","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","volume":"383","author":"P Kirchhof","year":"2020","unstructured":"Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, Fetsch T, van Gelder IC, Haase D, Haegeli LM, Hamann F, Heidb\u00fcchel H, Hindricks G, Kautzner J, Kuck KH, Mont L, Ng GA, Rekosz J, Schoen N, Schotten U, Suling A, Taggeselle J, Themistoclakis S, Vettorazzi E, Vardas P, Wegscheider K, Willems S, Crijns H, Breithardt G (2020) Early Rhythm-control therapy in patients with atrial fibrillation. N Engl J Med 383(14):1305\u20131316. https:\/\/doi.org\/10.1056\/NEJMoa2019422","journal-title":"N Engl J Med"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-024-02510-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-024-02510-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-024-02510-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T12:52:56Z","timestamp":1737982376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-024-02510-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["2510"],"URL":"https:\/\/doi.org\/10.1007\/s00392-024-02510-6","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"type":"print","value":"1861-0684"},{"type":"electronic","value":"1861-0692"}],"subject":[],"published":{"date-parts":[[2024,8,8]]},"assertion":[{"value":"18 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.M.Z. reports lecture fees\/honoraria and travel support by Medtronic, Boston Scientific, Abbott, Bayer Vital, Pfizer, ZOLL CMS. U.Z. reports lecture fees from AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, Pfizer. J.S. has received honoraria fees for research presentations of ARENA Registry. N. F. reports lecture fees from Astra Zeneca, Bayer Vital, Boehringer Ingelheim, Daiichi Sankyo and Pfizer. D.T. reports receiving lecture fees\/honoraria from Abbott, AstraZeneca, Bayer Vital, Boehringer Ingelheim Pharma, Bristol-Myers Squibb, Daiichi Sankyo, Johnson and Johnson Medical, Medtronic, Novartis, Pfizer Pharma, Sanofi-Aventis, and ZOLL CMS.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}